Core Viewpoint - Boyu Capital has increased its stake in Shanghai Henlius Biotech, Inc. by purchasing 262,500 and 80,000 H-shares, raising its holding from 5.84% to 7% [1][2]. Group 1: Investment Activity - Boyu Capital previously invested HKD 21.27 million to increase its stake from 4.89% to 5.15% on June 18, 2023, crossing the 5% threshold [2]. - The recent purchases reflect Boyu Capital's confidence in the core value and sustainable development potential of Shanghai Henlius in the innovative biopharmaceutical sector [2][3]. Group 2: Product Development and Clinical Progress - Shanghai Henlius has a robust pipeline with key products such as the anti-PD-1 monoclonal antibody Hansizhuang and the PD-L1 ADC HLX43, which have received international recognition for their clinical value [2][3]. - Recent data presented at the "2025 International Lung Cancer Frontier and Innovation Forum" confirmed the efficacy of HLX43 and HLX07, further enhancing market confidence in the company's R&D capabilities [3][5]. Group 3: Commercialization and International Collaboration - The company has established a diverse product matrix and has received global approvals for nine products, with four applications accepted by regulatory agencies in China, the US, and Europe [5]. - Shanghai Henlius has formed commercial partnerships with over 20 international pharmaceutical companies, covering major markets in Europe and the US, which supports its revenue growth [6]. - The company reported a significant increase in overseas product profits, with a 280% year-on-year growth in cash flow from BD contracts, indicating strong future revenue potential [6]. Group 4: Industry Outlook - As the biopharmaceutical industry enters a phase of high-quality development, companies with strong R&D capabilities and mature commercialization systems will become increasingly competitive [8]. - The continuous investment by top-tier capital like Boyu Capital serves as a testament to the intrinsic value demonstrated by Shanghai Henlius through solid clinical data [8].